Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer

Abstract

Tumor hypoxia contributes to therapy resistance and metastatic progression of locally advanced rectal cancer (LARC). We postulated that the tumor mitochondrial metabolism, manifested by reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) damage, reflects how hypoxic conditions connect to cancer-induced systemic inflammation and poor outcome. Levels of ROS and mtDNA damage were analyzed in three colorectal cancer (CRC) cell lines cultured for 24 hours under normoxia (21% O2) or hypoxia (0.2% O2) and serum sampled at the time of diagnosis from 35 LARC patients participating in a prospective therapy study. Compared with normoxia, ROS were significantly repressed and mtDNA damage was significantly enhanced in the hypoxic CRC cell lines; hence, a low ratio of ROS to mtDNA damage was an indicator of hypoxic conditions. In the LARC patients, low serum ROS were associated with elevated levels of circulating carcinoembryonic antigen and tumor choline concentration, both indicative of unfavorable biology, as well as adverse progression-free and overall survival. A low ratio of ROS to mtDNA damage in serum was associated with poor local tumor response to the neoadjuvant treatment and, of note, elevated systemic inflammation factors (C-reactive protein, the interleukin-1 receptor antagonist, and factors involved in tumor necrosis factor signaling), indicating that deficient treatment response locally and detrimental inflammation systemically link to a hypoxic mitochondrial metabolism. In conclusion, serum ROS and damaged mtDNA may be markers of the mitochondrial metabolism driven by the state of oxygenation of the primary tumor and possibly implicated in systemic inflammation and adverse outcome of LARC.

Translational Oncology (2019) 12, 76–83
Introduction

Colorectal cancer (CRC) is a heterogeneous disease of high molecular complexity [1] and, accordingly, therapeutic response disparities that necessitate individualized treatment [2]. In this context, the impact of tumor hypoxia must be taken into consideration since it constitutes one of the main mechanisms of tumor resistance to cytotoxic therapy (radiation and chemotherapy) [3] and is significantly correlated to metastatic disease progression [4]. Of particular note, a hypoxic tumor microenvironment supports protumor inflammatory responses and enhances the immune tolerance [5]. At the molecular level, hypoxia drives the tumor metabolism through alteration of oxygen-sensitive regulatory mechanisms, ultimately leading to increased glycolysis [6,7]. Additionally, the malignant phenotype promotes aerobic glycolysis because of diminished mitochondrial oxidative phosphorylation, the phenomenon known as the Warburg effect [8]. Collectively, the mitochondrial function is essential in balancing enhanced energy needs with substrate generation for biogenesis in rapidly growing tumor cells within a hypoxic microenvironment.

The partial reduction in tissue molecular oxygen produces reactive oxygen species (ROS) [9], of which about 90% can be traced back to the mitochondrial respiratory chain [10]. ROS levels are higher in malignant than in normal cells, which are a reflection of the hypermetabolic state of the former but also the selection of cells with augmented mitochondrial ROS (as a result of the lower requirement for molecular oxygen) during tumorigenesis [11]. ROS are central mediators in mitotic, angiogenic, and T-lymphocyte signaling in cancer [5,12]. However, malignant cells with stemness-like properties are vulnerable to excessive ROS [13]; thus, certain tumor cell populations may die from the same ROS context in which other populations thrive.

The human mitochondrial DNA (mtDNA) is a ~16.6-kilobase circular molecule encoding subunits of the enzyme complexes that drive oxidative phosphorylation. Due to its close proximity to the high energy-converting reactions, mtDNA is predisposed to oxidative damage [14]. Yet, considering the maintenance of mtDNA integrity, recent research has indicated a diverse repertoire of oxidative mtDNA insults and repair mechanisms [15]. Interestingly, mtDNA homeostasis is not restricted to the organelle, as mtDNA has been identified extramitochondrially as well as extracellularly. As shown in experimental models, the relocation into cytosol rises under hypoxia [16] and is capable of inducing a cytokine response [17,18]. While this particular process is ROS dependent [17], extracellular mtDNA release may occur independently of ROS [19]. In the circulation, cell-free mtDNA following cellular injury contributes to elicit the systemic inflammatory response [20–22].

The natural disease course of locally advanced rectal cancer (LARC), frequently growing as bulky tumors with predominant hypoxic regions within the pelvic cavity, makes this entity an event in a number of cases.

Materials and Methods

Cell Cultures

The human CRC cell lines HCT-116, HT-29, and LoVo were maintained in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% heat-inactivated fetal bovine serum (Gibco by Life Technologies, Grand Island, NY) and 2 mM L-glutamine (GE Healthcare–PAA Laboratories, Pasing, Austria). The cell lines were routinely tested and found free of mycoplasma infection, and identity was validated by short tandem repeat analysis. Prior to experiments, 1.0-1.5 × 10^6 cells (depending on the cell line) were seeded in T25 flasks and allowed to adhere for 24 hours in a humidified incubator containing 5% CO_2 before incubation for 24 hours under normoxic (21% O_2) or hypoxic (0.2% O_2) conditions, the latter obtained using the Invivo3 300 hypoxic chamber (Ruskinn Technologies, Leeds, UK). For ROS analysis, cell medium was collected, and cells were lysed by sonication in 500 μl PBS before the samples were stored at −80°C until analysis. For mtDNA damage analysis, cells were lysed in PBS containing protease K (diluted 1:10) before DNA isolation was undertaken as described below.

Ethics Approval and Consent to Participate

The two rectal cancer studies were approved by the Institutional Review Board and Regional Committee for Medical and Health Research Ethics of South-East Norway (reference numbers REK S-05059 and REK 2013/152) and were in accordance with the Helsinki Declaration. Written informed consent was required for participation.

The LARC-RRP Study

The patient population within the current report, which is from a prospective therapy study in rectal cancer (ClinicalTrials.gov NCT00278694), was enrolled from the 5 October 2005 to the 12 December 2009. Patient eligibility criteria, evaluation procedures, and review procedures of follow-up have been detailed previously [27]. Of particular note in the context of the mitochondrial metabolism, patients with diabetes mellitus were ineligible for study participation because of the significant risk of enhanced diabetes-induced sensory neuropathy by oxaliplatin [28], one of the study medications. Among the pleiotropic molecular mechanisms of the antidiabetic biguanide metformin, commonly prescribed for type 2 diabetes, is mitochondrial complex 1 inhibition [29]. For study-specific serum preparation at patient enrolment, blood was drawn in plain serum tubes with no additives for centrifugation to separate serum, which was left on ice for no more than 1 hour before storage at −80°C. Before the analyses for the current report, serum samples were centrifuged one more time (2000xg for 15 minutes) following hypoxia and its potential implication in cancer-induced systemic inflammation and adverse outcome. Prior to analysis of patient samples, the methods were established in a pertinent experimental setting using CRC cell cultures kept under normoxic and hypoxic conditions. Of particular note, we expanded the application of an in-house–developed high-resolution method that measures the proportion of damaged mtDNA-mediated inhibition of restriction enzyme cleavage of total mtDNA [25,26] into the first-time use in serum specimens, collected from LARC patients at the time of diagnosis. The patients had long-term follow-up after treatment of the primary tumor with curative intent but with metastatic failure as a progression event in a number of cases.
thawing. Patients were given neoadjuvant treatment consisting of short-course induction chemotherapy and sequential long-course chemoradiotherapy, both modalities containing oxaliplatin, before surgery 5-13 weeks after its completion [27]. The resected tumor specimens were histologically evaluated for the immediate local treatment response according to standard ypTN staging. In this patient population of mainly T3-4 stage disease, ypT0-2 outcome was considered as good response and ypT3-4 results as poor tumor shrinkage. Moreover, histological response was graded within one of five tumor regression grade (TRG) categories [30], where TRG1-2 was regarded as good histological regression and TRG3-5 as poor response. Regarding long-term progression-free survival (PFS; all PFS events were metastatic progression) and overall survival (OS), data were censored on the 8 August 2013, at which time 83% of study cases had been followed 5 years after enrolment.

**The OxyTarget Study**

Participants of this prospective biomarker study in rectal cancer (ClinicalTrials.gov NCT01816607), at present with immature outcome data, donated both whole blood on PAXgene Blood DNA Tubes (Qiagen Norge, Oslo, Norway), stored at −80°C, and serum at study enrolment. Serum was collected and processed in the same manner as described above.

**ROS Assessment**

Levels of ROS were determined applying the 96-well OxiSelect In Vitro ROS/RNS Assay Kit (Cell Biolabs, Inc., San Diego, CA), according to the manufacturer’s manual, essentially by the ability to oxidize dihydrochlorofluoroscein into a fluorescent derivative. Duplicate samples of cell lysate and medium (50 μl) and patient serum (25 μl), diluted 1:4 in PBS, were analyzed. For each sample, the mean value (obtained in nanomolar concentrations for the serum specimens) was used for downstream analyses.

**Assessment of Total Antioxidant Capacity (TAC)**

Serum TAC was determined applying the OxiSelect Total Antioxidant Capacity Assay Kit (Cell Biolabs, Inc.), according to the manufacturer’s manual, by the ability of copper (I), as reduced to provide concentrations in terms of copper-reducing equivalents, to react with a chromogenic reagent. Duplicate serum samples (20 μl), diluted 1:4 in PBS, were analyzed to provide concentrations in terms of copper-reducing equivalents, being proportional to the total reductive capacity.

**Quantification of mtDNA Damage**

This assay relies on the ability of a modification on the template DNA to inhibit restriction enzyme cleavage, as detailed previously [26]. Total DNA was isolated from cultured CRC cell lines, patients’ whole blood (50 μl), or serum samples (50 μl) using the DNeasy Blood & Tissue Kit (Qiagen Norge) according to the manufacturer’s instructions. Because this kit purifies total DNA, the amount of isolated nuclear DNA versus mtDNA was estimated by quantitative PCR analysis using primers for a nuclear gene (NDUFA9) and the mtDNA gene of interest, revealing 4- to 11-fold higher amounts of the latter in serum samples (not shown). A sequence flanking a TaqI restriction enzyme site in the 12S ribosomal RNA gene (MT-RNR1) was amplified using the forward (5′-AAACTGTCGGCAGAACACT-3′) and reverse (5′-CATGGGGCTACACCTTGACCT-3′) primers in the absence and presence of the enzyme. For quantitative PCR analysis, applied both for cell lines and patient samples, the resulting ΔCt was calculated as 

\[ C_{\text{TaqI}} - C_{\text{ct}} \]

with 

\[ C_{\text{TaqI}} \]

and 

\[ C_{\text{ct}} \]

corresponding to values of TaqI-digested and nondigested mtDNA, respectively. The frequency of mtDNA damage (i.e., resistant TaqI sites) was given by 2^ΔCt. For the droplet digital PCR (ddPCR), applied in analysis of 29 LARC-RRP serum specimens, samples were partitioned by the QX200 Droplet Generator (Bio-Rad Laboratories, Oslo) and analyzed with the QX200 Droplet Reader (Bio-Rad Laboratories). Data were given as the percentage of nondigested mtDNA [(mtDNA \text{TaqI} copies per μl – mtDNA nd copies per μl) × 100]. For these specimens, measures by quantitative PCR and ddPCR were correlated (r = 0.59; P = .001; by Pearson product correlation). The latter data set, representing the first-time application of ddPCR in combination with the particular method to measure mtDNA damage, was used in statistical analyses.

**Data Normalization**

Measured ROS levels showed significant interexperimental variations in the cell line studies. Thus, for ROS fluorescence and hence the ratios of ROS to mtDNA damage, the value of each data point was normalized with respect to the global mean of the respective setup, i.e., within each setup calculated as (ROS / global mean) × 100 and (ROS to mtDNA damage / global mean) × 100, respectively. Similarly, for the serum measures of ROS to mtDNA damage ratios, normalized data were used in downstream analyses.

**Analysis of Other Circulating Factors**

Routine blood tests were done within the standard patient workup. Exploration of selected inflammation factors in the study-specific serum samples was undertaken with a customized Luminex Multiplex Assay (R&D Systems, Minneapolis, MN).

**Analysis of Tumor Metabolites**

Tumor tissue was sampled at study enrolment as minuscule superficial biopsies endoluminally (i.e., by endoscopy), away from hypoxic tumor components invading beyond the bowel wall. The biopsies were analyzed by high-resolution magic angle spinning magnetic resonance spectroscopy, as detailed previously [31], to determine tissue concentration of 10 metabolites.

**Statistical Analysis**

Analyses were performed using IBM SPSS Statistics for Mac version 25.0 or GraphPad Prism version 7.0d. Groups were compared by Student’s t test. Correlations were determined by Pearson product correlation analysis after logarithmic transformation. PFS was calculated from the time of study enrolment to the date of distant metastasis, death of any cause, or end of follow-up, whichever occurred first. OS was measured from the date of enrolment to death of any cause or final censoring. Associations between variables related to ROS and mtDNA damage and either PFS or OS were analyzed with univariate Cox proportional hazards models, and results were presented as hazard ratio (HR) with 95% confidence interval (CI). All tests were two-sided. P values of less than .05 were considered statistically significant. The Benjamini-Hochberg method was applied, as appropriate, to account for the false discovery rate from multiple testing.

**Results**

**ROS in CRC Cell Cultures**

The HCT-116, HT-29, and LoVo cell lines were incubated under normoxia or hypoxia for 24 hours, and ROS were assessed.
Compared with the normoxic condition, the ROS level was significantly reduced in lysate from all of the three cell lines under hypoxia (Figure 1A). Medium from hypoxic HT-29 cells, but not from the two other cell lines, was also significantly lower in ROS content (Figure 1B). In order to obtain robust results that were not dependent of a particular cell line or the interexperimental variations, all normalized data from all of the cell lines were pooled. Hypoxic cells and their media showed significantly less ROS than the normoxic counterparts (Figure 1, A and B).

**Serum ROS at LARC Presentation**

Having established that extracellular ROS mirrored the intracellular level in the CRC models, we next analyzed serum ROS in a balanced sample selection of 35 patients (17 females and 18 males, 18 T2-3 and 17 T4 cases) from the entire LARC-RRP study population [27]. The patients had no evidence of disease disseminated outside the pelvic cavity at diagnosis. Median age was 62 (range, 31-73) years. As shown in Table 1, the ROS level [median 180 (range, 20.0-666) nM] was weakly correlated with body mass index [median 24 (range, 17-34) kg/m²] but not age. Moreover, higher ROS were seen with higher hemoglobin [median 13.3 (range, 9.6-15.2) g/dl], while inverse correlations were found with thrombocytes [median 329 (range, 177-990) × 10⁹/l], leukocytes [median 7.3 (range, 4.5-16.2) × 10⁹/l], neutrophils [median 4.8 (range, 2.5-12.8) × 10⁹/l], and the CRC tumor marker carcinoembryonic antigen [median 4.0 (range, 0-156) μg/l]. In a subset of 16 patients with available data from high-resolution magic angle spinning magnetic resonance spectroscopy, a strong negative correlation was noted between serum ROS and tumor choline [median 0.37 (range, 0.25-1.6) μmol/g of tissue], which is a precursor for phosphocholine in cellular membranes [32], indicating that ROS generation and release may be lower in rapidly proliferating tumors with an active membrane phospholipid metabolism [33]. However, ROS levels were not significantly different in T4 versus T2-3 cases, or in females and males (Table 2).

**Damaged mtDNA in CRC Cell Cultures**

Next, mtDNA damage was quantified in the three cell lines following exposure to normoxia or hypoxia for 24 hours (Figure 1C). Compared with the respective normoxic condition, the frequency of mtDNA damage was significantly higher in hypoxic HCT-116 and HT-29 cells but not in the LoVo cell line. Again, when all data from all of the cell lines were pooled, hypoxic cells showed significantly
more mtDNA damage than the normoxic counterparts. As depicted in Figure 1D, acknowledging the indicated dependence of ROS (Figure 1, A and B) and mtDNA damage (Figure 1C) to hypoxia, a low ratio of ROS to mtDNA damage might be an indicator of hypoxic CRC.

**Damaged mtDNA in Serum Versus Whole Blood**

The arithmetic ratio of ROS to mtDNA damage might also provide information of tumor hypoxia in CRC patients if feasible to measure in the circulation. The commercial OxiSelect In Vitro ROS/RNS Assay Kit used in the current analyses of cell line and serum samples might in principle have been applied as a diagnostic assay. In contrast, our assay for quantification of mtDNA damage was developed to analyze cells or tissues [26]. In order to investigate if this assay might also allow measurement of mtDNA damage in the noncellular compartment of blood, we took advantage of the parallel sampling of PAXgene whole blood and serum in the OxyTarget study for rectal cancer. As shown in Figure 2, analysis of specimens from six randomly selected patients (5 males and 1 female, age 56–76 years, disease stage T2–4N0–2M0) eligible for neoadjuvant oncologic therapy demonstrated detectable damaged mtDNA which in serum, Table 2. Circulating ROS and Damaged mtDNA and Correlations with Tumor Metabolic Factors

| Metabolic Factor | n | r   | P   | P Adjusted |
|------------------|---|-----|-----|------------|
| Lactate          | 35| 0.12| .47 | NA         |
| Taurine          | 35| 0.35| .040| NA         |
| Hemoglobin       | 35| 0.37| .030| NA         |
| Thromboxytes     | 35| 0.49| .003| NA         |
| Leukocytes       | 35| 0.38| .023| NA         |
| Neuropilin       | 35| 0.39| .020| NA         |
| Lymphocytes      | 35| 0.11| .53 | NA         |
| Monocytes        | 35| 0.22| .21 | NA         |
| CEA              | 35| 0.34| .046| NA         |
| Choline          | 16| 0.68| .004| 0.040      |
| Glycophosphocholine | 16| 0.56| .022| 0.17       |
| Glucose          | 15| 0.40| .14 | 0.17       |
| Myoepinositol    | 14| 0.33| .26 | 0.17       |
| Phosphocholine   | 16| 0.23| .40 | 0.17       |
| Taurine          | 15| 0.14| .62 | 0.17       |
| Glycine          | 15| 0.07| .81 | 0.17       |
| Lactate          | 16| 0.02| .94 | 0.17       |
| Creatine         | 16| 0.20| .94 | 0.17       |
| Alanine          | 16| 0.01| 0.98| 0.17       |

BMI, body mass index; CEA, carcinoembryonic antigen; NA, not applicable; ROS, reactive oxygen species.

1 According to the Benjamini-Hochberg method with a false discovery rate set at 0.05.

2 Calculated as body weight in kilograms divided by the height in meters square.

---

**Figure 2.** mtDNA damage in rectal cancer patients' whole blood and serum. Values are shown as mean ± standard deviation of triplicate measurements of specimens from six randomly selected patients (P1–P6), as well as all respective values pooled from the OxyTarget biomarker study. *P < 0.05 on comparison of values from whole blood and serum.

---

**Table 2. Circulating ROS and Damaged mtDNA and Correlations with Tumor Metabolic Factors**

| Metabolic Factor | n | r   | P   | P Adjusted |
|------------------|---|-----|-----|------------|
| Lactate          | 35| 0.13| .47 | NA         |
| Taurine          | 35| 0.35| .040| NA         |
| Hemoglobin       | 35| 0.37| .030| NA         |
| Thromboxytes     | 35| 0.49| .003| NA         |
| Leukocytes       | 35| 0.38| .023| NA         |
| Neuropilin       | 35| 0.39| .020| NA         |
| Lymphocytes      | 35| 0.11| .53 | NA         |
| Monocytes        | 35| 0.22| .21 | NA         |
| CEA              | 35| 0.34| .046| NA         |
| Choline          | 16| 0.68| .004| 0.040      |
| Glycophosphocholine | 16| 0.56| .022| 0.17       |
| Glucose          | 15| 0.40| .14 | 0.17       |
| Myoepinositol    | 14| 0.33| .26 | 0.17       |
| Phosphocholine   | 16| 0.23| .40 | 0.17       |
| Taurine          | 15| 0.14| .62 | 0.17       |
| Glycine          | 15| 0.07| .81 | 0.17       |
| Lactate          | 16| 0.02| .94 | 0.17       |
| Creatine         | 16| 0.20| .94 | 0.17       |
| Alanine          | 16| 0.01| 0.98| 0.17       |

BMI, body mass index; CEA, carcinoembryonic antigen; NA, not applicable; ROS, reactive oxygen species.

1 According to the Benjamini-Hochberg method with a false discovery rate set at 0.05.

2 Calculated as body weight in kilograms divided by the height in meters square.

---

**Table 3. Circulating ROS to Damaged mtDNA Ratio and Correlations with Circulating Inflammatory Factors**

| Inflammatory Factor | n | r   | P   | P Adjusted |
|---------------------|---|-----|-----|------------|
| CRP                 | 27| −0.60| .001| NA         |
| CD40                | 16| −0.44| .086| .18        |
| CXCL1               | 16| 0.17| .54 | .65        |
| CXCL2               | 16| 0.18| .50 | .65        |
| CXCL5               | 16| −0.51| .044| .11        |
| IFN (IFNγ)          | 16| −0.52| .038| .11        |
| IL1R (IL1ra)        | 16| −0.80| .000| .000       |
| IL4                 | 16| 0.064| .81 | .81        |
| IL10                | 16| −0.35| .19 | .32        |
| IL12B               | 16| −0.28| .30 | .45        |
| S100A8              | 16| −0.41| .12 | .23        |
| TNF (TNFα)          | 16| −0.63| .009| .045       |
| TNFRSF1A (TNFR1)    | 16| −0.61| .013| 0.049      |
| TNFRSF10B (TRAILR2) | 16| −0.64| .007| 0.045      |
| TNFRSF10C (TRAILR3) | 16| −0.90| .74 | .81        |

CRP, C-reactive protein; IFNγ, interferon-γ; IL1ra, interleukin-1 receptor antagonist; mtDNA, mitochondrial DNA; NA, not applicable; ROS, reactive oxygen species; TNFα, tumor necrosis factor-α; TNFR1, TNF receptor 1; TRAILR2, TNF-related apoptosis-inducing ligand receptor 2; TRAILR3, TNF-related apoptosis-inducing ligand receptor 3.

1 Each protein is listed by the gene name with the commonly used protein name in brackets if different from the former.

2 According to the Benjamini-Hochberg method with a false discovery rate set at 0.05.

3 Measurement was lacking for two cases.
likely as cell-free molecules, was in significantly lower quantity than in whole blood for the majority of patients.

**Serum ROS Versus TAC**

However, the serum ratio of ROS to mtDNA damage might not be informative in the actual clinical context if the ROS effects are counterbalanced by antioxidant defense mechanisms. We therefore used the OxyTarget serum biobank to directly compare ROS and TAC levels in 12 randomly selected patients (9 males and 3 females, age 48-67 years, disease stage T2-4N0-2M0-1). The individual ROS levels [median 100 (range, 18.5-130) nM] did not correlate with the corresponding TAC values [median 1.21 (range, 0.94-1.45) mM] (r = 0.45; P = .14; by Pearson product correlation). Moreover, since the extent of the variance from the median value was wider for the ROS measures than for TAC despite the former being several orders of magnitude lower, the individual patient’s serum ROS level was probably independent of the overall reductive capacity.

**Serum ROS and Damaged mtDNA in LARC Outcome**

ROS and the ratio of ROS to mtDNA damage at the time of diagnosis were measured in stored serum biobank samples (collected at patient enrolment, 2005-2009) from the selected LARC-RRP study patients, who following diagnosis had been given an intensified neoadjuvant treatment regimen before the pelvic surgery [27]. Analysis of mtDNA damage was technically successful in 29 of the 35 cases, and the proportion of damaged mtDNA varied from 0.60% to 7.2% (not shown). As shown in Table 2, lower serum ratio of ROS to mtDNA damage was associated with poor histological tumor response to the neoadjuvant therapy (ypT3-4 stage and TRG3-5 scores; P = .023 and P = .044, respectively), but ROS as isolated measure was not. The local treatment response is regarded an indicative surrogate marker of long-term outcome in LARC [34], but in the case of PFS and OS, it was higher ROS level that was associated with favorable outcome (PFS: HR 0.52, 95% CI 0.29-0.93, P = .028; OS: HR 0.49, 95% CI 0.26-0.95, P = .034). While 5-year PFS was 54%, 71% of patients were alive after 5 years. For cases with recorded PFS events or death at censoring, median time to development of metastatic disease was 17 (range, 4-52) months and 27 (range, 1-57) months to death. When censored, median follow-up time was 65 (range, 45-65) months for patients still alive.

**Serum ROS and Damaged mtDNA in LARC Inflammation**

Finally, we found strong inverse correlations between the ratio of ROS to damaged mtDNA and serological markers of systemic inflammation in the LARC-RRP patients (Table 3), i.e., the levels of C-reactive protein [CRP; median 10 (range, 1-248) mg/l] and, in a subset of 16 patients with available data, interleukin-1 receptor antagonist [IL1ra; median 825 (range, 400-6204) ng/l] and factors involved in tumor necrosis factor (TNF) signaling: TNFα [median 30.8 (range, 28.8-42.6) ng/l], TNF receptor-1 [TNFR1; median 4.46 (range, 2.62-173) μg/l] and TNF-related apoptosis-inducing ligand receptor-2 [TRAILR2; median 70.7 (range, 58.8-138) ng/l].

**Discussion**

Presuming that the mitochondrial metabolism connects tumor hypoxia to systemic inflammation and adverse outcome of LARC, we assessed ROS and mtDNA damage in three CRC cell lines as template for the succeeding examination of these factors in patients’ circulation. The cell line experiments unambiguously demonstrated the combination of repressed ROS and enhanced mtDNA damage under hypoxia. In LARC patients, low serum ROS at the time of diagnosis were associated with an elevated level of circulating carcinoembryonic antigen and tumor choline concentration, both indicative of unfavorable biology [33,35], as well as adverse long-term outcome (PFS and OS). Likewise, a low ratio of ROS to mtDNA damage in serum was associated with poor local tumor response to the neoadjuvant treatment and, of note, elevated systemic inflammation factors. Our strategy identified circulating ROS and cell-free damaged mtDNA as potential markers of the mitochondrial metabolism driven by the state of oxygenation of the primary tumor and possibly implicated in systemic inflammation and adverse outcome of LARC.

Malignant cells are regarded to be higher in mitochondrial ROS production than normal cells, and this ROS may stabilize the molecular effects of hypoxia [11,12]. In this context, the reduced ROS associated with hypoxic treatment of the CRC cell lines might reflect one or more of multiple respiratory chain adaptations [36], if not an incipient selection over the 24-hour treatment period toward stemness-like cell populations thriving in hypoxic conditions [13]. Contrary to the classic view that mtDNA base lesions are induced by ROS [14], hypoxic treatment with repressed ROS in the three CRC cell lines explicitly enhanced mtDNA damage. Importantly, ROS as such are not reflecting the submitochondrial level of peroxide, which has higher propensity for damaging mtDNA [37].

For the LARC patients, serum ROS were independent of age and sex. It was not surprising that subjects with higher hemoglobin, i.e., better tissue oxygenation capacity, had higher ROS. The inverse correlation with tumor choline probably reflected insufficient oxygenation of rapidly proliferating tumors, which may further have contributed in the observed correlation between high ROS and favorable long-term outcome, as hypoxia is a main mechanism of tumor resistance to cytotoxic therapy [3] and metastatic progression [4]. However, the isolated ROS measure was not predictive of local treatment outcome of the neoadjuvant therapy; instead, patients with a low serum ratio of ROS to mtDNA damage were at higher risk of poor histological tumor response. Collectively, this set of data indicates that low circulating ROS alone or in combination with heightened mtDNA release, provided both reflected the generation by the patients’ intrapelvine tumor manifestations, were associated with tumor and systemic factors indicative of detrimental disease biology. In this context, it would have been valuable to have insight into the hypoxic tumor fraction; however, the available endoscopic tumor samples did not represent relevant tumor components for this purpose.

Perhaps most intriguingly, though data were available for only a subset of patients, the inverse connection between ROS and mtDNA damage in serum showed strong correlations with CRP, measured in clinical practice as a general marker of inflammation, as well as with IL1ra, TNFα, TNFR1, and TRAILR2—higher levels of these factors were found in patients with lower ROS and higher mtDNA damage. The inverse correlations between ROS and counts of thrombocytes, leukocytes, and neutrophils, commonly elevated in the inflammatory response, were also in line with these findings. Reported investigations of the role of circulating cell-free mtDNA in systemic inflammation comprise total mtDNA—not damaged mtDNA—primarily in nonmalignant conditions [20–22]. Interestingly, we detected significantly lower mtDNA damage in serum than in whole blood for four of six examined patients, implying a preference for extracellular release of intact over damaged mtDNA molecules. Although unraveling the biological impact of circulating mtDNA in
cancer is still in its infancy, it was recently shown that extracellular vesicles provide metabolically functional mtDNA that supports metastatic progression [38]. The specific mtDNA damage analyzed in the current report appeared at rather low occurrence. Furthermore, we cannot rule out tissues of origin other than the rectal primary tumor. Nevertheless, the strong correlation of a low ROS to mtDNA damage ratio with a deficient treatment response locally along with detrimental systemic inflammation, the latter likely cancer-induced in the study subjects [39], implies causality. IL1ra has not been much investigated in oncology. High circulating levels of this factor as well as of TNFα correlated with ex vivo cytotoxic activity of neutrophils in breast cancer patients, but the clinical implications of these findings are not known [40]. In patients with coronary artery disease, however, high circulating IL1ra correlated with elevated CRP and were independently predictive for adverse outcome [41]. While the TNFα-TNFRI1 signaling pathway has been thoroughly studied in inflammatory bowel disease and CRC development, its precise function in established CRC and treatment response has not yet been determined [42]. Experimental studies have shown that TRAILR2, in addition to its cell death-inducing activity, is involved in activation of proinflammatory gene transcription programs, cell proliferation, and cell migration [43].

There are evident limitations of this hypothesis-generating exploration. First, the cohort is small, and results must be interpreted cautiously. On the other hand, the selected LARC-RP study population was balanced in terms of sex and T2-3 versus T4 stage disease and representative for age groups in which rectal cancer prevails [44]. These factors did not confound the subjects’ circulating components of the tumor mitochondrial metabolism. Only body mass index was higher in individuals with higher ROS, but the correlation was weak. Next, the analyses reported here had not been planned at the time of study conduct. Hence, the observed inverse correlation between the individual study patient’s serum ROS and mtDNA damage and correlations between these factors and patients’ local and systemic disease manifestations might be chance findings. Nevertheless, the association between low serum ROS (reflecting tissue hypoxia) and rapidly proliferating tumors (in terms of tumor choline) was strong even in the low number of patients with available data. This was also the case for ROS (molecules diffusing freely) and cell-free damaged mtDNA (likely tumor-released) with regard to inflammation factors in the circulation. A prospective therapy study incorporating explorative investigations that cover such aspects could provide further mechanistic insights.

In conclusion, our study provided data suggesting that low ROS and high cell-free mtDNA damage in the circulation reflect tumor hypoxia and contribute to cancer-induced systemic inflammation and thereby an adverse outcome of LARC. It might be that these findings have revealed a previously unheeded mechanism of the host response to aggressive cancer.

The Role of the Funding Sources

The funding sources had no role in the study design; collection, analysis, and interpretation of data; writing of the report; or the decision to submit the article for publication.

References

[1] Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Teijpar S, and Tabernero J (2017). Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 17, 268. https://doi.org/10.1038/nrc.2017.24.

[2] Punt CJ, Koopman M, and Vermeulen L (2017). From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol 14, 235–246. https://doi.org/10.1038/nrclinonc.2016.171.

[3] Begg AC, Stewart FA, and Venn C (2011). Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11, 239–253. https://doi.org/10.1038/ nrc3007.

[4] Lu and Kang Y (2010). Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 16, 5928–5935. https://doi.org/10.1158/1078-0432.CCR-10-1360.

[5] Triner D and Shah YM (2016). Hypoxia-inducible factors: a central link between inflammation and cancer. J Clin Invest 126, 3689–3698. https://doi.org/10.1172/JCI84430.

[6] Bertout JA, Patel SA, and Simon MC (2008). The impact of O2 availability on human cancer. Nat Rev Cancer 8, 967–975. https://doi.org/10.1038/nrc2540.

[7] Wouters BG and Kortzinsky M (2008). Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8, 851–864. https://doi.org/10.1038/nrc2501.

[8] Wallace DC (2012). Mitochondria and cancer. Nat Rev Cancer 12, 685–698. https://doi.org/10.1038/nrc3365.

[9] Sullivan LB, Gui DY, and Heiden MG (2016). Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer 16, 680–693. https://doi.org/10.1038/nrc2016.85.

[10] Murphy MP (2009). How mitochondria produce reactive oxygen species. Biochem J 417, 1–13. https://doi.org/10.1042/BJ20081386.

[11] Sullivan LB and Chandel NS (2014). Mitochondrial reactive oxygen species and cancer. Cancer Metab 2, 17. https://doi.org/10.1186/2049-3002-2-17.

[12] Diebold L and Chandel NS (2016). Mitochondrial ROS regulation of proliferating cells. Free Radic Biol Med 100, 86–93. https://doi.org/10.1016/j.freeradbiomed.2016.04.198.

[13] Yang M, Liu P, and Huang P (2016). Cancer stem cells, metabolism, and therapeutic significance. Tumour Biol 37, 5735–5742. https://doi.org/10.1007/s13277-016-4945-5.

[14] Takes FM and Van Houten B (1997). Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following stress. Proc Natl Acad Sci USA 94, 514–519.

[15] Alexeyev M, Shokolenko I, Wilson G, and LeDoux S (2013). The maintenance of mitochondrial DNA integrity—critical analysis and update. Cold Spring Harb Perspect Biol 5, a012641. https://doi.org/10.1101/cshperspect.a012641.

[16] Liu Y, Yan W, Tohme S, Chen M, Fu Y, and Tian D, et al (2015). Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9, J Hepatol 63, 114–121. https://doi.org/10.1016/j.jhep.2015.02.009.

[17] Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, and Lam HC, et al (2011). Autophagy proteins regulate innate immune responses by inhibiting the unfolded protein response in cancer. Nat Immunol 12, 222–230. https://doi.org/10.1038/ni.1980.

[18] Shimada K, Crother TR, Karfin J, Dagvadorj J, Chiba N, and Chen S, et al (2012). Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36, 401–414. https://doi.org/10.1016/j.immuni.2012.01.009.

[19] Ingelsson B, Soderberg D, Strid T, Soderberg A, Bergh AC, and Loito V, et al (2018). Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C. Proc Natl Acad Sci USA 115, E478–487. https://doi.org/10.1073/pnas.1711950115.

[20] Nakahira K, Hisata S, and Choi AM (2015). The roles of mitochondrial damage-associated molecular patterns in diseases. Antioxid Redox Signal 23, 1329–1350. https://doi.org/10.1089/ars.2015.6407.

[21] West AP and Shadel GS (2017). Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat Rev Immunol 17, 363–375. https://doi.org/10.1038/nri.2017.21.

[22] Zhang Q, Raoof M, Chen Y, Sumi Y, Sursel T, and Junger W, et al (2010). Circulating mitochondria from TCM patients cause inflammatory responses to injury. Nature 464, 104–107. https://doi.org/10.1038/nature08790.

[23] Bosset JF, Calais G, Miteur L, Maingon P, Stojanovic-Rundic S, and Bensadoun RJ, et al (2014). Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15, 184–190. https://doi.org/10.1016/S1470-2045(13)70599-0.

[24] Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, and Arnold D, et al (2015). Oxaliplatin added to fluorouracil-based preoperative 

Translational Oncology Vol. 12, No. 1, 2019
chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* **16**, 979–989. https://doi.org/10.1016/S1470-2045(15)00159-X.

[25] Wang W, Oyenbroch P, Skinnes R, Esbensh E, Bjoras M, and Eide L (2010). Mitochondrial DNA integrity is essential for mitochondrial maturation during differentiation of neural stem cells. *Stem Cells* **28**, 2195–2204. https://doi.org/10.1002/stem.542.

[26] Wang W, Scheffler K, Esbensh E, and Eide L (2016). Quantification of DNA damage by real-time qPCR. *Methods Mol Biol* **1351**, 27–32. https://doi.org/10.1007/978-1-4939-3040-1_3.

[27] Dueland S, Ree AH, Groholt KK, Follvord S, and Hole KH, et al (2016). Oxaliplatin-containing preoperative therapy in locally advanced rectal cancer: local response, toxicity and long-term outcome. *Clin Oncol (R Coll Radiol)* **28**, 532–539. https://doi.org/10.1016/j.clon.2016.01.014.

[28] Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, and van de Poll-Franse LV (2013). Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. *J Clin Oncol* **31**, 2609–2707. https://doi.org/10.1200/JCO.2013.49.1514.

[29] Cameron AR, Logie L, Patel K, Erhardt S, Bacon S, and Middleton P, et al (2013). Oxaliplatin induces death receptor CD95, TRAILR1, and TRAILR2. *J Pathol* **229**, 187–197. https://doi.org/10.1002/path.4197.

[30] Bouzourene H, Bosman FT, Scelentag W, Matter M, and Coucke P (2002). Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. *Cancer* **94**, 1121–1130.

[31] Redalen KR, Sitter B, Barthén TF, Groholt KK, Hole KH, and Dueland S, et al (2016). High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer. *Radiat Oncol* **118**, 393–398. https://doi.org/10.1016/radonc.2015.11.031.

[32] Gibellini F and Smith TK (2010). The Kennedy pathway—de novo synthesis of phosphatidylethanolamine and phosphatidylcholine. *J UMBL Life* **62**, 414–428. https://doi.org/10.1002/jub.337.

[33] Gliunde K, Bhujwalla ZM, and Ronen SM (2011). Choline metabolism in malignant transformation. *Nat Rev Cancer* **11**, 835–848. https://doi.org/10.1038/nrc3162.

[34] Akdim M and Eng C (2011). The current landscape of locally advanced rectal cancer. *Nat Rev Clin Oncol* **8**, 649–659. https://doi.org/10.1038/nrclinonc.2011.118.

[35] Duffy MJ (2015). Personalized treatment for patients with colorectal cancer: role of biomarkers. *Biomark Med* **9**, 337–347. https://doi.org/10.2217/bmm.15.3.

[36] Fuhrmann DC and Brune B (2017). Mitochondrial composition and function under the control of hypoxia. *Redox Biol* **12**, 208–215. https://doi.org/10.1016/j.redox.2017.02.012.

[37] Logas A, Shabalina IG, Prime TA, Regarti S, Kalinovich AV, and Hartley RC, et al (2014). In vivo levels of mitochondrial hydrogen peroxide increase with age in mtDNA mutator mice. *Aging Cell* **13**, 765–768. https://doi.org/10.1111/ace.12121.

[38] Sansone P, Savini C, Kurelec I, Chang Q, Amato LB, and Strillacci A, et al (2017). Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. *Proc Natl Acad Sci U S A* **114**, E9066–9075. https://doi.org/10.1073/pnas.1704862114.

[39] McMillan DC (2013). The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. *Cancer Treat Rev* **39**, 534–540. https://doi.org/10.1016/j.ctrv.2012.08.003.

[40] Comen E, Wojnarowicz P, Seshan VE, Shah R, Colker C, and Norton L, et al (2016). TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients. *NPJ Breast Cancer* **2**, 6009. https://doi.org/10.1038/npjbcancer.2016.9.

[41] Schofer N, Ludwig S, Rubsamen N, Schnabl R, Lackner KJ, and Ruprecht HJ, et al (2018). Prognostic impact of Interleukin-1 receptor antagonist in patients with documented coronary artery disease. *Int J Cardiol* **257**, 24–29. https://doi.org/10.1016/j.ijcard.2018.01.055.

[42] Jurjus A, Eid A, Al Kattar S, Zeenny MN, Gerges-Gagea A, and Haydar H, et al (2016). Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: the links. *BBA Clin* **1**, 16–24. https://doi.org/10.1016/j.bbagen.2015.11.002.

[43] Siegmund D, Lang I, and Wajant H (2017). Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2. *FEBS J* **284**, 1131–1159. https://doi.org/10.1111/febs.13968.

[44] Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rozario S, Coebergh JW, and Comber H, et al (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer* **49**, 1374–1403. https://doi.org/10.1016/j.ejca.2012.12.027.